Progress in the treatment of breast cancer in the elderly

Annals of Oncology

Volumn 13, Issue SUPPL. 4, 2002, Pages 207-210

  Aapro, M S ^a  

^a CLINIQUE DE GENOLIER   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CAPECITABINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; EXEMESTANE; FLUOROURACIL; LETROZOLE; METHOTREXATE; PROGESTERONE RECEPTOR; TAMOXIFEN;

AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE METASTASIS; BREAST CANCER; BREAST CARCINOMA; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DRUG EFFICACY; ECHOMAMMOGRAPHY; ELDERLY CARE; FEMALE; HEMATOLOGIC MALIGNANCY; HORMONAL THERAPY; HUMAN; PARTIAL MASTECTOMY; PRIORITY JOURNAL; SEGMENTAL MASTECTOMY; SOLID TUMOR; SURGICAL MORTALITY; UTERUS CANCER;

EID: 0036434632     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdf661     Document Type: Article

References (27)

1. Castiglione M, Gelber RD, Goldhirsch A. Adjuvant systemic therapy for breast cancer in the elderly: competing causes of mortality. International Breast Cancer Study Group. J Clin Oncol 1990; 8: 519-526.
2. Clark GM. The biology of breast cancer in older women. J Gerontol 1992; 47: 19-23.
3. Fish EB, Chapman JA, Link MA. Competing causes of death for primary breast cancer. Ann Surg Oncol 1998; 5: 368.
4. Extermann M, Aapro M. Assessment of the older cancer patient. Hematol Oncol Clin North Am 2000; 14: 63-77.
5. Repetto L, Fratino L, Audisio RA et al. Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. J Clin Oncol 2002; 20: 494-502.
6. Gazet JC, Ford HT, Coombes RC et al. Prospective randomized trial of tamoxifen versus surgery in elderly patients with breast cancer. Eur J Surg Oncol 1994; 20: 207-214.
7. Robertson JF, Ellis IO, Elston CW et al. Mastectomy or tamoxifen as initial therapy for operable breast cancer in elderly patients: 5-year follow-up. Eur J Cancer 1992; 28A: 908-910.
8. Bates T, Riley DL, Houghton J et al. Breast cancer in elderly women: a Cancer Research Campaign trial comparing treatment with tamoxifen and optimal surgery with tamoxifen alone. The Elderly Breast Cancer Working Party. Br J Surg 1991; 78: 591-594.
9. Mustacchi G, Ceccherini R, Pluchinotta A et al. Results of adjuvant treatment in breast cancer women aged more than 70: Italian Cooperative Group experience. Tumori 2002; 88 (1 Suppl. 1): S83-S85.
10. Dixon JM, Love CD, Bellamy CO et al. Letrozole as primary medical therapy for locally advanced and large operable breast cancer. Breast Cancer Res Treat 2001; 66: 191-199.
11. Miller WR, Dixon JM. Endocrine and clinical endpoints of exemestane as neoadjuvant therapy. Cancer Control 2002; 9: 9-15.
12. Eiermann W, Paepke S, Appfelstaedt J et al. Letrozole Neo-Adjuvant Breast Cancer Study Group. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized doubleblind multicenter study. Ann Oncol 2001; 12: 1527-1532.
13. Wazer DE, Erban JK, Robert NJ et al. Breast conservation in elderly women for clinically negative axillary lymph nodes without axillary dissection. Cancer 1994; 74: 878.
14. Amsterdam E, Birkenfield S, Gilad A, Krispin M. Surgery for carcinoma of the breast in women over 70 years of age. J Surg Oncol 1987; 35: 180.
15. Svastics E, Sulyok Z, Besznyak I. Treatment of breast cancer in women older than 70 years of age. J Sing Oncol 1989; 41: 19.
16. Samain E, Schauvliège F, Marty J. Anesthesia for breast cancer surgery in the elderly. Crit Rev Oncol Hematol 2002; in press.
17. Veronesi U, Marubini E, Mariani L et al. Radiotherapy after breast-conserving surgery in small breast carcinoma: long-term results of a randomized trial. Ann Oncol 2001; 12: 997-1003.
18. Kantorowitz DA, Poulter CA, Rubin P et al. Treatment of breast cancer with segmental mastectomy alone or segmental mastectomy plus radiation. Radiother Oncol 1989; 15: 141-150.
19. Hughes KS, Schnaper L, Berry D et al. Comparison of lumpectomy plus tamoxifen with and without radiotherapy (RT) in women 70 years of age or older who have clinical stage I, estrogen receptor positive (ER+) breast carcinoma. Proc Am Soc Clin Oncol 2001; 20: (Abstr 93).
20. Anonymous. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998; 351: 1451.
21. Anonymous. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998; 352: 930.
22. The ATAC (arimidex, tamoxifen alone or in combination) Trialists' group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002; 359: 2131-2139.
23. Ellis MJ, Coop A, Singh B et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001; 19: 3808-3816.
24. van 't Veer LJ, Dai H, van de Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530-536.
25. Fargeot P, Roche H, Bonneterre JM et al. Disease-free survival (DFS) advantage of weekly epirubicin plus tamoxifen versus tamoxifen (Tam) alone as adjuvant treatment of operable, node-positive (N+) elderly breast cancer (BC) patient (pts): 5-year follow-up results of French Adjuvant Study Group, FASG-08 trial. Proc Am Soc Clin Oncol 2002; 21: 37a (Abstr 145).
26. Mouridsen H, Gershanovich M, Sun Y et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001; 19: 2596-2606.
27. Bonneterre J, Buzdar A, Nabholtz JM et al. Arimidex Writing Committee. Investigators Committee Members. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 2001; 92: 2247-2258.